POSC110 Cost-Effectiveness of Durvalumab Following Chemoradiotherapy in Unresectable Stage III NSCLC Patients in the US: An Update Based on 5-Year Pacific Data
| Autor: | Mooradian, MJ, Taylor, S, Ramsden, R, van Keep, M, Dunlop, W, Brannman, L, Yong, C |
|---|---|
| Zdroj: | In Value in Health January 2022 25(1) Supplement:S108-S108 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|
Full Text from ScienceDirect